Clinical Trial

Surgical Safety Technologies Celebrates Transformational Growth in 2024

NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Surgical Safety Technologies (SST), the pioneer and leading provider of ambient technology healthcare…

11 months ago

Inato Launches AI-Powered Patient Pre-Screening to Reduce Site Burden and Accelerate Enrollment

NEW YORK and PARIS, Jan. 28, 2025 /PRNewswire/ -- Inato, the leading platform for clinical trial access and inclusivity, today…

11 months ago

Metabolon Scientists Dr. Adam Kennedy and Dr. Greg Michelotti to Guest Edit MDPI’s Metabolites Journal

Special issue "Advances in Metabolomics for Precision Medicine: From Biomarker Discovery to Clinical Applications" focuses on the latest challenges and…

11 months ago

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset,…

11 months ago

Corsair Pharma Partners with InstantGMP® to Ensure Quality for Clinical Trials

CARY, N.C., Jan. 28, 2025 /PRNewswire/ -- InstantGMP™, a leader in fully integrated GMP-compliant software solutions for pharmaceutical manufacturing, proudly…

11 months ago

BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs

Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial…

11 months ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Dual-Targeted CD19/CD70 Allogeneic CAR T: Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune…

11 months ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a…

11 months ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to…

11 months ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with…

11 months ago